BR790

BR790 is an orally administered small molecule SHP2 modulator under development for the treatment of advanced solid tumors, including non-small cell lung cancer, colorectal cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. It acts by modulating the activity of Src homology-2 domain-containing protein tyrosine phosphatase 2 (SHP2), a key regulator in multiple oncogenic signaling pathways. The drug is being developed primarily by Jiangxi Qingfeng Pharmaceutical and Shanghai Gopherwood Biotech, with clinical trials ongoing in China. Its mechanism targets tumor growth through interference with SHP2-mediated signaling pathways that are often dysregulated in cancers. Clinical studies have evaluated both monotherapy and combination therapy (notably with tislelizumab) to assess safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy[1][3][4][7].